Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Honey and Nigella Sativa for COVID-19 Prophylaxis
NCT04767087Phase 3Unknown
- Start
- Mar 2021
- Primary completion
- Feb 2022
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial (2 arms). Primary endpoint: SARS-CoV-2 infection rate at 14 days. Status: unknown.
Beyond the preview
Go deeper on NCT04767087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04767087.